Login
Beyondspring Inc logo

Beyondspring Inc

beyondspringpharma.com

What Do They Do?

Develops Plinabulin and other drug candidates for cancer patients, and works with pharmaceutical companies on medicines that target proteins for breakdown.

Who Are Their Customers?

Pharmaceutical companies collaborate on drug discovery and commercialization: Hengrui is the Plinabulin commercialization partner in Greater China, while Eli Lilly and Eisai work with SEED on drug discovery.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
Revenue
vs $0 in Q2 FY2025
Net income
▼ −53% (Loss)
vs −$1.8M in Q2 FY2025
  • Sep 17, 2026 Nasdaq notified the company of a bid-price listing-rule deficiency The shares continue to trade during a 180-day period to regain compliance.
  • Jun 4, 2026 The company appointed a new CEO and CFO Lan Huang transitioned from CEO to board chair, while Min Qiu became CEO and Na Li became CFO.

SEED's pipeline advances SEED's earlier description centered on its drug-discovery platform and collaborations; the latest report says its wholly owned lead oncology drug has entered clinical studies.

Who Do They Compete With?

Competes with Bristol-Myers Squibb, Merck &, and Eli Lilly

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support